Article

FDA Approves Generic Lidocaine Ointment

SunGen Pharma, the specialty pharmaceutical company, has received its eighth ANDA approval from the FDA.

SunGen Pharma has received FDA approval for an abbreviated new drug application approval for Lidocaine Ointment USP, 5%. The drug product is used for the production of anesthesia of accessible mucous membranes of the oropharynx.

The product is also used as an anesthetic lubricant for intubation and for the temporary relief of pain associated with minor burns, including sunburn, abrasions of the skin, and insect bites.

Lidocaine has annual sales of about $60 million.

REFERENCE

SunGen Pharma receives eighth ANDA approval from US FDA [news release]. Princeton, NJ; October 31, 2019: Globe Newswire. https://www.globenewswire.com/news-release/2019/10/31/1939048/0/en/SunGen-Pharma-Receives-Eighth-ANDA-Approval-from-US-FDA.html. Accessed October 31, 2019.

Related Videos
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
Pharmacy, Advocacy, Opioid Awareness Month | Image Credit: pikselstock - stock.adobe.com
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Hurricane Helene, Baxter plant, IV fluids shortage, health systems impact, injectable medicines, compounding solutions, patient care errors, clinical resources, operational consideration, fluid conservation, sterile water, temperature excursions, training considerations, patient safety, feedback request
Image Credit: © peopleimages.com - stock.adobe.com
Pharmacists, Education, Advocacy, Opioid Awareness Month | Image Credit: Jacob Lund - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards